ENTITY
Regeneron Launches $500M Venture Fund Led by Former Executives
Regeneron/ venture fund/ $500 million/ biotech/ former executives/ innovation/ investment/ 2024.
The Transformative Future of Specialist Distribution: Adaptive Strategies and Technological Innovations
Specialist Distribution, Future Trends, Adaptive Strategies, Technological Innovations, Automation, Artificial Intelligence, Last-Mile Solutions, Virtual Distribution, Data Integration, Global Expansion, Smart Distribution Centers
Optimizing Pharmaceutical Supply Chains: The Evolving Role of Third-Party Logistics Providers
Third-Party Logistics (3PL) Providers, Pharmaceutical Supply Chain, Pharma 4.0, Regulatory Compliance, Cold Chain Management, Data Mining and Management, Licensing Requirements
Neumora Therapeutics’ Schizophrenia Drug NMRA-266 Faces FDA Hold Over Convulsions in Rabbits
Neumora, United States Food and Drug Administration, NMRA-266, Seizures, Schizophrenia
Life Sciences Senior Associate: Evaluating Opportunities in Therapeutics, Diagnostics, and Health Tech
Life Sciences Senior Associate, Therapeutics, Diagnostics, Research Tools, Health Technology, Opportunity Evaluation, Diligence
EU Approves Illumina’s Divestment Plan for Cancer Test Maker Grail
Illumina, Grail, EU clearance, Divestment, European Commission, Cancer diagnostic subsidiary, Capitalization terms
European Commission Grants Approval for Illumina to Divest Grail
Illumina, Grail, European Commission, Divestment, Competition, Antitrust
Fujifilm Diosynth Announces $1.2B Expansion in North Carolina, Aiming to Employ 1,400
Fujifilm Diosynth Biotechnologies, $1.2 billion expansion, North Carolina, Holly Springs, 1/400 jobs, Biopharmaceutical manufacturing, End-to-end cell culture CDMO facility, Japanese investment
Enlivex Stock Plunges 50% Following Mixed Phase II Sepsis Results for Allocetra Cell Therapy
Enlivex Therapeutics, Allocetra Cell Therapy, Phase II Study, Sepsis Treatment, Stock Plummet, Mixed Results, Septic Shock, Urinary Tract Infection (UTI)
AstraZeneca’s FASENRA Gains FDA Approval for Add-On Maintenance Treatment of Severe Asthma in Children Aged 6-11
AstraZeneca, FASENRA, Benralizumab, Severe Asthma, Pediatric Label Expansion, FDA Approval, Children Aged 6-11